These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 8803374)

  • 1. Re: control of cancer-related pain with MS contin.
    O'Bryan-Tear CG; Kinnersley N
    J Pain Symptom Manage; 1996 Sep; 12(3):145-6. PubMed ID: 8803374
    [No Abstract]   [Full Text] [Related]  

  • 2. The use of controlled release morphine sulfate (MS Contin) in Queensland 1990-1993.
    Arnold P
    Med J Aust; 1995 Nov; 163(10):559. PubMed ID: 8538536
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacoeconomics evaluation of morphine, MS contin and oxycodone in the treatment of cancer pain.
    Zhang WZ; Yu WJ; Zhao XL; He BX
    Asian Pac J Cancer Prev; 2014; 15(20):8797-800. PubMed ID: 25374210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, safety, and steady-state pharmacokinetics of once-a-day controlled-release morphine (MS Contin XL) in cancer pain.
    Hagen NA; Thirlwell M; Eisenhoffer J; Quigley P; Harsanyi Z; Darke A
    J Pain Symptom Manage; 2005 Jan; 29(1):80-90. PubMed ID: 15652441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guidelines for the use of MS Contin tablets in the management of cancer pain.
    Warfield CA
    Postgrad Med J; 1991; 67 Suppl 2():S9-12; discussion S13. PubMed ID: 1758825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine.
    Payne R; Mathias SD; Pasta DJ; Wanke LA; Williams R; Mahmoud R
    J Clin Oncol; 1998 Apr; 16(4):1588-93. PubMed ID: 9552070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose morphine for moderate cancer pain.
    Baker H
    Lancet Oncol; 2016 Feb; 17(2):e47. PubMed ID: 26710710
    [No Abstract]   [Full Text] [Related]  

  • 8. When oral morphine fails in cancer pain: the role of the alternative routes.
    Mercadante SG
    Am J Hosp Palliat Care; 1998; 15(6):333-42. PubMed ID: 9866456
    [No Abstract]   [Full Text] [Related]  

  • 9. Cancer pain management.
    Portenoy RK
    Clin Adv Hematol Oncol; 2005 Jan; 3(1):30-2. PubMed ID: 16166965
    [No Abstract]   [Full Text] [Related]  

  • 10. Planning for breakthrough cancer pain.
    McCaffery M; McKitrick LF
    Am J Nurs; 1996 Jun; 96(6):24. PubMed ID: 8651330
    [No Abstract]   [Full Text] [Related]  

  • 11. [The feature and direction of each controlled release morphine].
    Kimura N; Noguchi T
    Nihon Rinsho; 2007 Jan; 65(1):29-34. PubMed ID: 17233412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New morphine preparations with extended effect duration. 2 treatment observations].
    Kim DJ; Jankowska H; Dierke-Dzierzon C; Sturm M; Lindena G
    MMW Fortschr Med; 2000 May; 142(18):49. PubMed ID: 10851871
    [No Abstract]   [Full Text] [Related]  

  • 13. The use of controlled-release morphine sulfate (MS Contin) in Queensland 1990-1993.
    Richards AH
    Med J Aust; 1995 Aug; 163(4):181-2. PubMed ID: 7651250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended-release epidural morphine (DepoDur).
    Pasero C; McCaffery M
    J Perianesth Nurs; 2005 Oct; 20(5):345-50. PubMed ID: 16246812
    [No Abstract]   [Full Text] [Related]  

  • 15. Experience with a controlled-release oral morphine for cancer pain management.
    Kim BS; Chung HC
    Postgrad Med J; 1991; 67 Suppl 2():S82-6. PubMed ID: 1758823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, multi-site, crossover, placebo-controlled equivalence study of morning versus evening once-daily sustained-release morphine sulfate in people with pain from advanced cancer.
    Currow DC; Plummer JL; Cooney NJ; Gorman D; Glare PA
    J Pain Symptom Manage; 2007 Jul; 34(1):17-23. PubMed ID: 17601560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Sustained-release Opioids: Morphine, Oxycodone and Tapentadol].
    Takahashi Y; Iseki M
    Masui; 2015 Nov; 64(11):1133-40. PubMed ID: 26689063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term rectal administration of high-dose sustained-release morphine tablets.
    Walsh D; Tropiano PS
    Support Care Cancer; 2002 Nov; 10(8):653-5. PubMed ID: 12436225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic treatment of cancer pain.
    Bruera E; Fainsinger RL
    N Engl J Med; 1997 Mar; 336(13):962-3; author reply 963. PubMed ID: 9072703
    [No Abstract]   [Full Text] [Related]  

  • 20. Buprenorphine in long-term control of chronic pain in cancer patients.
    Pace MC; Passavanti MB; Grella E; Mazzariello L; Maisto M; Barbarisi M; Baccari E; Sansone P; Aurilio C
    Front Biosci; 2007 Jan; 12():1291-9. PubMed ID: 17127381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.